New Zealand markets closed

G1 Therapeutics, Inc. (GTHX)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
10.65-1.41 (-11.69%)
At close: 04:00PM EST
10.69 +0.04 (+0.38%)
After hours: 07:51PM EST
Full screen
Trade prices are not sourced from all markets
Previous close12.06
Open12.13
Bid10.55 x 1400
Ask10.67 x 3200
Day's range10.51 - 12.13
52-week range10.51 - 37.07
Volume1,623,820
Avg. volume953,930
Market cap452.86M
Beta (5Y monthly)N/A
PE ratio (TTM)N/A
EPS (TTM)N/A
Earnings date22 Feb 2022 - 28 Feb 2022
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est41.00
  • GlobeNewswire

    G1 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    RESEARCH TRIANGLE PARK, N.C., Dec. 01, 2021 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, today announced the grant of inducement stock options exercisable for an aggregate of 101,700 shares of G1’s common stock to seven employees under the G1 Therapeutics, Inc. 2021 Inducement Equity Incentive Plan (the “Inducement Plan”), and an aggregate of 56,400 shares of G1’s common stock to eight employees under the previously-announced G1 Therapeutics, Inc

  • GlobeNewswire

    G1 Therapeutics Initiates Phase 2 Trial to Support the Antitumor Mechanism of Action (MOA) of Trilaciclib in the Tumor Microenvironment

    New Trial Designed to Further Investigate the Immune-Based MOA of Trilaciclib and Help Determine Future Target Tumor Types and Treatment CombinationsRESEARCH TRIANGLE PARK, N.C., Dec. 01, 2021 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, today announced that the Company has initiated a Phase 2, single arm, open-label study of trilaciclib in patients with early-stage triple negative breast cancer (TNBC) designed to further investigate the role of

  • GlobeNewswire

    G1 Therapeutics Announces Initiation of New Phase 2 Trial of Trilaciclib in Combination with the Antibody-Drug Conjugate (ADC), Trodelvy® (Sacituzumab Govitecan-Hziy)

    Trial Will Evaluate Anti-Tumor Efficacy and Myeloprotection Endpoints in Patients with Unresectable Locally Advanced or Metastatic Triple-Negative Breast Cancer (TNBC)RESEARCH TRIANGLE PARK, N.C., Nov. 29, 2021 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, today announced that the Company has initiated a Phase 2, single arm, open-label study of trilaciclib administered prior to the antibody-drug conjugate (ADC), Trodelvy® (sacituzumab govitecan-hz